Last reviewed · How we verify
Photofrin (porfimer)
Photofrin (generic name: porfimer) is a Photoactivated Radical Generator drug developed by Concordia Labs Inc. It is currently FDA-approved (first approved 1995) for Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia, High Grade Dysplasia associated with Barrett's Esophagus, Malignant tumor of esophagus.
Photofrin is a photosensitizer used in photodynamic therapy for various conditions, including breast cancer, skin cancer, hepatocellular carcinoma, and obstructive jaundice. It works as a DNA inhibitor, a small molecule that targets DNA.
At a glance
| Generic name | porfimer |
|---|---|
| Sponsor | Concordia Labs Inc |
| Drug class | Photoactivated Radical Generator |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
| First approval | 1995 |
Approved indications
- Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia
- High Grade Dysplasia associated with Barrett's Esophagus
- Malignant tumor of esophagus
- Non-small cell lung cancer
Common side effects
- Photosensitivity reaction
- Pleural effusion
- Dyspnea
- Pneumonia
- Pyrexia
- Anemia
- Constipation
- Nausea
- Abdominal pain
- Vomiting
- Chest pain
- Edema
Key clinical trials
- Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery (PHASE1)
- Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma (PHASE2)
- Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (PHASE1)
- Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma (PHASE2)
- Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer (PHASE1,PHASE2)
- Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer (PHASE1)
- Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium (PHASE2)
- Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Photofrin CI brief — competitive landscape report
- Photofrin updates RSS · CI watch RSS
- Concordia Labs Inc portfolio CI
Frequently asked questions about Photofrin
What is Photofrin?
What is Photofrin used for?
Who makes Photofrin?
What is the generic name of Photofrin?
What drug class is Photofrin in?
When was Photofrin approved?
What development phase is Photofrin in?
What are the side effects of Photofrin?
Related
- Drug class: All Photoactivated Radical Generator drugs
- Manufacturer: Concordia Labs Inc — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Endoscopic Photodynamic Ablation Adjunct for Cancer or High Grade Dysplasia
- Indication: Drugs for High Grade Dysplasia associated with Barrett's Esophagus
- Indication: Drugs for Malignant tumor of esophagus
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing